Nothing Special   »   [go: up one dir, main page]

SG11201408292YA - Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same - Google Patents

Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same

Info

Publication number
SG11201408292YA
SG11201408292YA SG11201408292YA SG11201408292YA SG11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA
Authority
SG
Singapore
Prior art keywords
international
gyeonggi
inhalation formulation
dry powder
suwon
Prior art date
Application number
SG11201408292YA
Inventor
Kyeong Soo Kim
Deokkyu Lee
Dong Ho Kim
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11201408292YA publication Critical patent/SG11201408292YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/187626 A1 (51) International Patent Classification: A61K 9/14 (2006.01) A61K31/56 (2006.01) A61K9/16 (2006.01) A61K31/166 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/KR2013/004880 3 June 2013 (03.06.2013) English English (30) Priority Data: 10-2012-0063665 14 June 2012 (14.06.2012) KR (71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeong- gi-do 445-910 (KR). (72) Inventors: KIM, Kyeong Soo; 113-1902, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). LEE, Deokkyu; 1222-402, 50, Mokdongdong-ro, Yangcheon- gu, Seoul 158-772 (KR). KIM, Dong Ho; 809-ho, 12, Seongnam-daero 172beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-853 (KR). KIM, Yong II; 147-2201, 57, Hwasan-ro, Paldal-gu, Suwon-si, Gyeonggi-do 442-872 (KR). PARK, Jae Hyun; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-737 (KR). WOO, Jong Soo; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-330 (KR). (74) Agent: FIRSTLAW P.C.; Trust Tower, 275-5, Yang- jae-Dong, Seocho-Ku, Seoul 137-739 (KR). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: DRY POWDER FOR INHALATION FORMULATION COMPRISING SALMETEROL XINAFOATE, FLUTIC­ ASONE PROPIONATE AND TIOTROPIUM BROMIDE, AND METHOD FOR PREPARING SAME Aerodynamic size distribution salmeterol of CJ i> 00 i-H en i-H o CJ o & O) m o & C0 M— o E 3 CO El Example 1 Example 1 (Handyhaler®) • 10 Urnim • 30 L/mim Z2 60 L/mim Ofl 90 L/mim Example 5 Comp. Ex. 2 Comp. Ex. 3 (57) Abstract: Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tio - tropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The invent - ive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribu - tion in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon ad - ministration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
SG11201408292YA 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same SG11201408292YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120063665A KR20130140358A (en) 2012-06-14 2012-06-14 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing the same
PCT/KR2013/004880 WO2013187626A1 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same

Publications (1)

Publication Number Publication Date
SG11201408292YA true SG11201408292YA (en) 2015-01-29

Family

ID=49758405

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408292YA SG11201408292YA (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same

Country Status (19)

Country Link
US (2) US9283232B2 (en)
EP (1) EP2861219A4 (en)
JP (1) JP2015519394A (en)
KR (1) KR20130140358A (en)
CN (1) CN104363895A (en)
AU (1) AU2013275113A1 (en)
BR (1) BR112014030910A2 (en)
CA (1) CA2876283A1 (en)
HK (1) HK1206602A1 (en)
IL (1) IL236198A0 (en)
IN (1) IN2014DN11257A (en)
MX (1) MX2014014755A (en)
NZ (1) NZ703788A (en)
PH (1) PH12014502746A1 (en)
RU (1) RU2015100905A (en)
SG (1) SG11201408292YA (en)
TW (1) TWI565481B (en)
WO (1) WO2013187626A1 (en)
ZA (1) ZA201500208B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4235142A3 (en) 2014-06-30 2023-11-22 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
MA41378A (en) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc DRY POWDER INHALER CONSISTING OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
KR20160117069A (en) 2015-03-31 2016-10-10 한미약품 주식회사 Capsule for inhalation with improved stability of combined active ingredients
JP6940416B2 (en) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Multi-agent brittle matrix composition
EP3426329A4 (en) 2016-03-09 2019-11-13 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN108066329B (en) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 Preparation method of microparticles of fluticasone or derivatives thereof for inhalation
KR102696616B1 (en) * 2018-12-21 2024-08-20 한미약품 주식회사 Dry powder for inhalation formulation and preparation method thereof
KR102330428B1 (en) * 2019-10-14 2021-11-24 한미약품 주식회사 Dry powder for inhalation formulation and preparation method thereof
AU2021296221A1 (en) * 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide
CN115266987B (en) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 Pharmaceutical composition for treating respiratory diseases
CN115792071A (en) * 2022-12-01 2023-03-14 南京联智医药科技有限公司 Method for analyzing related substances of Tiger ammonium bromide intermediate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20100063016A1 (en) * 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
KR20100063116A (en) * 2007-09-12 2010-06-10 글락소 그룹 리미티드 Novel combination of therapeutic agents
EP2321023B1 (en) * 2008-07-18 2016-06-15 Prosonix Limited Process for improving crystallinity of fluticasone particles
US20110253140A1 (en) * 2008-07-30 2011-10-20 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
TR201000681A2 (en) 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations inhaled.

Also Published As

Publication number Publication date
TWI565481B (en) 2017-01-11
EP2861219A1 (en) 2015-04-22
TW201402154A (en) 2014-01-16
CN104363895A (en) 2015-02-18
IN2014DN11257A (en) 2015-10-09
US9549936B2 (en) 2017-01-24
RU2015100905A (en) 2016-08-10
HK1206602A1 (en) 2016-01-15
ZA201500208B (en) 2016-10-26
BR112014030910A2 (en) 2017-06-27
KR20130140358A (en) 2013-12-24
US20150283151A1 (en) 2015-10-08
PH12014502746B1 (en) 2015-02-02
AU2013275113A1 (en) 2015-02-05
NZ703788A (en) 2016-10-28
US20150157566A1 (en) 2015-06-11
MX2014014755A (en) 2015-02-24
WO2013187626A1 (en) 2013-12-19
IL236198A0 (en) 2015-01-29
CA2876283A1 (en) 2013-12-19
EP2861219A4 (en) 2015-10-28
JP2015519394A (en) 2015-07-09
PH12014502746A1 (en) 2015-02-02
US9283232B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
SG11201408292YA (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805120YA (en) Zika virus vaccine
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407340YA (en) Treatment of myelosuppression
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201407110QA (en) Novel dosage form and formulation of abediterol
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201805001UA (en) Method of treating influenza a
SG11201804050QA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201402986RA (en) Kinase inhibitors
SG11201900471VA (en) Combination therapy for copd
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201408273TA (en) Time synchronizing of distinct video and data feeds that are delivered in a single mobile ip data network compatible stream
SG11201805142RA (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative